Cargando…
A Phase Ib Study of Durvalumab (MEDI4736) in Combination with Carbon-Ion Radiotherapy and Weekly Cisplatin for Patients with Locally Advanced Cervical Cancer (DECISION Study): The Early Safety and Efficacy Results
We conducted a phase Ib study to examine the safety of a combination of carbon-ion RT (CIRT) with durvalumab (MEDI4736; AstraZeneca) in patients with locally advanced cervical cancer. This was an open-label, single-arm study with a modified 3 + 3 design. Patients with newly diagnosed histologically...
Autores principales: | Okonogi, Noriyuki, Murata, Kazutoshi, Yamada, Shigeru, Habu, Yuji, Hori, Makoto, Kurokawa, Tomoya, Inaba, Yosuke, Fujiwara, Tadami, Fujii, Yasuhisa, Hanawa, Michiko, Kawasaki, Yohei, Hattori, Yoko, Suzuki, Kazuko, Tsuyuki, Kyoko, Wakatsuki, Masaru, Koto, Masashi, Hasegawa, Sumitaka, Ishikawa, Hitoshi, Hanaoka, Hideki, Shozu, Makio, Tsuji, Hiroshi, Usui, Hirokazu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10342070/ https://www.ncbi.nlm.nih.gov/pubmed/37445743 http://dx.doi.org/10.3390/ijms241310565 |
Ejemplares similares
-
Phase Ib study of durvalumab (MEDI4736) in combination with carbon-ion radiotherapy and weekly cisplatin for patients with locally advanced cervical cancer (DECISION study): study protocol for a prospective open-label single-arm study
por: Okonogi, Noriyuki, et al.
Publicado: (2022) -
Safety and efficacy of durvalumab (MEDI4736) in various solid tumors
por: Yang, Hui, et al.
Publicado: (2018) -
Phase Ib/II study to evaluate the safety and antitumor activity of durvalumab (MEDI4736) and tremelimumab as monotherapy or in combination, in patients with recurrent or metastatic gastric/gastroesophageal junction adenocarcinoma
por: Kelly, Ronan J, et al.
Publicado: (2015) -
Forthcoming Phase II Study of Durvalumab (MEDI4736) Plus Chemotherapy for Small Cell Lung Cancer with Brain Metastases
por: Shiraishi, Yoshimasa, et al.
Publicado: (2022) -
A Phase I study to evaluate the safety and antitumor activity of durvalumab (MEDI4736) in combination with tremelimumab in patients with advanced solid tumors
por: Papadopoulos, Kyriakos P, et al.
Publicado: (2015)